ISSN: 2348-6295

Journal of Pharma Creations (JPC)

JPC |Vol.12 | Issue 4 | Oct - Dec -2025

www.pharmacreations.com

DOI : https://doi.org/10.61096/jpc.v12.iss4.2025.281-292

Review

Hybrid Nanocarriers: Synergistic Drug Delivery Platforms Combining Polymers, Lipids, and Inorganic Materials

D. Kumarasamyraja[1]*, Nivetha S. R[2], M. Vimalraj[3]

[1,2,3] *PGP College of Pharmaceutical Science and Research Institute, Namakkal, Tamilandu, India*

*Author for Correspondence: Dr. D.Kumarasamyraja
Email: ksrajapharma83@gmail.com

Published on: 19.12.2025

Published by:
Futuristic Publications

Abstract

The evolution of drug delivery systems has witnessed a paradigm shift from conventional dosage forms toward nanocarrier-based platforms that enable precise, controlled, and site-specific release of therapeutic agents. Among these, hybrid nanocarriers engineered constructs that integrate the complementary features of polymers, lipids, and inorganic materials represent an emerging frontier in nanomedicine. These systems overcome the limitations of single-component nanocarriers by leveraging synergistic properties such as structural stability, biocompatibility, controlled release kinetics, and stimuli-responsive behavior. Hybrid nanocarriers offer the capacity to encapsulate diverse classes of drugs, including small molecules, peptides, nucleic acids, and biologics, thereby expanding the scope of precision medicine. The incorporation of polymers enhances mechanical strength and tunable drug release; lipids contribute biocompatibility, membrane fusion capacity, and stealth properties; while inorganic nanomaterials provide imaging capabilities, magnetic responsiveness, and photothermal or photodynamic functionalities. Collectively, these platforms enable multifunctional drug delivery strategies suited for oncology, infectious diseases, neurodegenerative disorders, and regenerative medicine. This review systematically analyzes the structural design, physicochemical attributes, fabrication strategies, and therapeutic applications of polymer–lipid–inorganic hybrid nanocarriers. Special emphasis is placed on their role in overcoming multidrug resistance, enhancing intracellular drug trafficking, achieving spatiotemporal control of release, and enabling theranostic approaches. Current translational hurdles, including large-scale reproducibility, toxicity concerns, and regulatory frameworks, are also critically discussed. The future perspective highlights the potential of artificial intelligence-guided formulation design, patient-specific customization, and integration with smart biomedical devices to drive the clinical translation of these hybrid systems.

Keywords: Hybrid nanocarriers; polymer–lipid–inorganic systems; synergistic drug delivery; multifunctional nanomedicine; theranostics.

1.0 Introduction

Nanocarrier-based therapeutics have revolutionized modern pharmacotherapy by enhancing solubility, prolonging circulation, and enabling targeted delivery of drugs to pathological sites. However, single-component nanocarriers, whether polymeric, lipidic, or inorganic, often face intrinsic limitations such as insufficient stability, uncontrolled burst release, poor drug loading, or lack of multifunctionality. To address these shortcomings, hybrid nanocarriers combining polymers, lipids, and inorganic materials have emerged as a next-generation platform that unites the benefits of each material class while mitigating their disadvantages. Such synergistic systems are capable of delivering hydrophobic and hydrophilic drugs simultaneously, co-encapsulating small molecules with biologics, and integrating diagnostic and therapeutic functionalities into a single construct [1,2]. The rationale for hybridization arises from the principle of complementarity. Polymers offer structural stability, biodegradability, and controllable release profiles through chemical modification of functional groups. Lipids, with their biomimetic nature, provide high biocompatibility, stealth properties against immune clearance, and efficient endosomal escape mechanisms. Inorganic nanomaterials such as gold, silica, or iron oxide contribute unique optical, magnetic, and catalytic properties, enabling imaging, photothermal therapy, and stimuli-responsive release [3,4]. By combining these attributes, hybrid nanocarriers embody multifunctional drug delivery systems with tunable architecture and performance.

Recent literature has demonstrated the potential of hybrid nanocarriers in diverse therapeutic landscapes. In oncology, polymer–lipid–inorganic hybrids have been engineered for combined chemotherapy, gene silencing, and photothermal therapy, significantly improving tumor regression compared to single systems [5]. In neurological disorders, lipid-polymer hybrids coated with magnetic nanoparticles facilitate blood–brain barrier penetration and enable MRI-guided drug delivery [6]. Furthermore, in infectious disease management, hybrid systems have shown improved intracellular drug delivery to macrophages and biofilm disruption [7]. Such wide- ranging applicability highlights the transformative potential of these constructs in clinical medicine. This review provides a comprehensive account of hybrid nanocarriers, beginning with a detailed description of their classification and fabrication strategies, followed by discussion of their physicochemical properties, therapeutic applications, and translational challenges. Emphasis is placed on recent innovations from the past eight years to reflect the cutting-edge progress in this evolving field.

2.0 Classification of Hybrid Nanocarriers

The classification of hybrid nanocarriers can be approached from multiple perspectives, including their structural configuration, material composition, and functional design. The most common framework involves categorizing them into polymer–lipid hybrids, polymer–inorganic hybrids, lipid–inorganic hybrids, and fully ntegrated polymer–lipid–inorganic systems. Each of these classes provides unique physicochemical attributes and therapeutic functionalities, thereby allowing tailored applications for different disease conditions [8,9].

2.1 Polymer–Lipid Hybrid Nanocarriers

Polymer–lipid hybrids represent one of the most widely explored systems due to their balance between structural stability and biological compatibility. Typically, they consist of a polymeric core surrounded by a lipid shell, resembling liposomes but with improved drug encapsulation and controlled release. The polymer provides robustness and controlled degradation, while the lipid layer enhances stealth properties and reduces opsonization. Applications include targeted delivery of anticancer drugs, siRNA, and poorly soluble compounds [10].

2.2 Polymer–Inorganic Hybrid Nanocarriers

This class integrates polymers with inorganic nanoparticles such as mesoporous silica, gold, or iron oxide. The polymer serves as a functional coating or encapsulant, imparting biocompatibility, stimuli-responsiveness, or extended release. The inorganic core confers additional features such as imaging (MRI, CT, fluorescence), hyperthermia generation, or catalysis. Such hybrids are particularly promising in theranostic applications where diagnosis and therapy can be combined in a single construct [11].

2.3 Lipid–Inorganic Hybrid Nanocarriers

Lipid–inorganic hybrids typically involve inorganic nanoparticles encapsulated or coated within lipid bilayers. The lipid layer ensures compatibility with biological membranes, while the inorganic component provides diagnostic or therapeutic enhancement. For instance, gold nanoparticles coated with lipid bilayers can function as photothermal agents as well as drug carriers, offering dual functionality [12].

2.4 Fully Integrated Polymer–Lipid–Inorganic Systems

The most advanced category is the fully integrated polymer–lipid–inorganic nanocarriers, which incorporate all three components into a single construct. These systems exploit the complementary strengths of each material, resulting in highly multifunctional platforms. For example, polymer cores for stability, lipid shells for stealth, and gold nanoshells for photothermal therapy can be combined to create tri-functional nanocarriers capable of targeted chemotherapy, real-time imaging, and thermal ablation simultaneously [13].

3.0 Fabrication Strategies for Hybrid Nanocarriers

The fabrication of hybrid nanocarriers requires precise integration of multiple materials while maintaining reproducibility, scalability, and stability. Methods are chosen depending on the desired architecture, physicochemical properties, and therapeutic applications. Common strategies include nanoprecipitation, emulsification–solvent evaporation, thin-film hydration, layer-by-layer assembly, microfluidics, and templating approaches [14,15].

3.1 Nanoprecipitation and Self-Assembly

Nanoprecipitation involves dissolving polymers and drugs in a suitable organic solvent followed by controlled mixing with an aqueous phase containing lipids or surfactants. Rapid solvent diffusion results in the spontaneous assembly of hybrid nanoparticles. This method is simple, reproducible, and suitable for hydrophobic drugs but may have limitations for hydrophilic drug encapsulation [16].

3.2 Emulsification–Solvent Evaporation

In this approach, polymer solutions containing drug molecules are emulsified in an aqueous lipid solution, followed by solvent evaporation. This produces a stable polymer core coated with lipids, mimicking a liposome but with superior drug encapsulation and release control. Emulsification methods are particularly effective for co-delivery of hydrophilic and hydrophobic molecules [17].

3.3 Thin-Film Hydration and Post-Insertion Techniques

Thin-film hydration is commonly used for lipid–polymer hybrids. Lipid films are hydrated with an aqueous solution containing preformed polymer nanoparticles or inorganic cores, leading to self-assembly into hybrid nanostructures. Post-insertion of targeting ligands or polyethylene glycol (PEG) chains further enhances stealth and targeting capabilities [18].

3.4 Layer-by-Layer (LbL) Assembly

LbL assembly involves sequential deposition of oppositely charged polymers, lipids, or nanoparticles onto a template core, creating a multilayered hybrid structure. This method allows fine-tuning of thickness, surface charge, and drug release behavior, making it suitable for precision medicine applications [19].

3.5 Microfluidics and Template-Assisted Methods

Microfluidic platforms enable high-throughput, reproducible, and scalable fabrication of hybrid nanocarriers with precise size control. Templating approaches, using mesoporous silica or polymeric templates, allow construction of complex architectures that are later functionalized with lipids and inorganic components. Such methods represent the future of clinical translation owing to their reproducibility and scalability [20].

4.0 Physicochemical Properties of Hybrid Nanocarriers

The physicochemical characteristics of hybrid nanocarriers play a decisive role in dictating their biological performance, including biodistribution, cellular uptake, clearance, and therapeutic efficacy. Since hybrid systems integrate polymers, lipids, and inorganic materials, their properties can be finely modulated to optimize performance. The most critical parameters include particle size and morphology, surface charge, stability, drug loading capacity, release kinetics, and responsiveness to physiological or external stimuli [21,22]. Particle size is central to in vivo performance because it determines circulation half-life, extravasation into pathological tissues, and clearance through renal or hepatic pathways. For instance, hybrid nanocarriers in the size range of 50–200 nm are optimal for tumor accumulation via the enhanced permeability and retention (EPR) effect while avoiding rapid renal elimination [23]. Morphology, including spherical, rod-shaped, or core–shell structures, influences membrane interaction and intracellular trafficking. Polymer–lipid–inorganic hybrids often exhibit spherical core–shell morphologies with tunable rigidity. Surface charge is equally important, as positively charged hybrids can enhance cellular uptake via electrostatic interactions with negatively charged membranes but may also trigger opsonization and rapid clearance. Conversely, neutral or PEGylated surfaces prolong systemic circulation. Stability in physiological media is improved by the lipid layer, while polymers confer mechanical strength against premature disintegration. Inorganic components such as silica or gold further stabilize the architecture and may provide rigidity to prevent deformation [24].

Drug loading capacity and release kinetics are strongly determined by the interplay between polymer matrices, lipid bilayers, and inorganic carriers. Hydrophobic drugs partition into polymer or lipid phases, while hydrophilic and charged molecules can be complexed via electrostatic or hydrogen bonding interactions. Mesoporous inorganic cores, such as silica nanoparticles, allow exceptionally high drug loading, which is then modulated by lipid or polymer coatings [25]. Another defining property is responsiveness to stimuli. Hybrid nanocarriers can be engineered to respond to pH, redox gradients, enzymatic activity, temperature, magnetic fields, or light. For example, polymer-coated gold nanorods encapsulated in lipid bilayers can undergo photothermal disruption upon near-infrared irradiation, enabling spatiotemporally controlled release at the tumor site [26]. Such "smart" responsiveness enhances t herapeutic precision while minimizing off-target toxicity. The interplay of these physicochemical features highlights the superiority of hybrid systems compared to single-material nanocarriers, offering tunable, multifunctional, and clinically relevant properties.

5.0 Drug Loading and Release Mechanisms

Drug loading and release are pivotal to the therapeutic potential of hybrid nanocarriers. Unlike single-component systems, hybrids offer multiple compartments and physicochemical interactions that allow co-loading of different classes of drugs and precise modulation of release kinetics [27,28].

5.1 Encapsulation and Loading Strategies

Drugs can be incorporated into hybrid nanocarriers by physical entrapment, adsorption, covalent conjugation, or electrostatic interactions. In polymer–lipid hybrids, hydrophobic drugs are commonly entrapped within the polymeric core or lipid bilayer, while hydrophilic drugs are encapsulated in the aqueous compartments. Inorganic cores such as mesoporous silica allow surface functionalization with amines, thiols, or carboxyl groups to anchor drug molecules through covalent linkages [29]. Advanced strategies include co-encapsulation of small molecules with nucleic acids (DNA, siRNA, mRNA) or proteins, enabling combination therapy. For instance, cationic polymer–lipid hybrids can complex siRNA electrostatically while simultaneously entrapping hydrophobic chemotherapeutics in the lipid bilayer, providing a synergistic platform for overcoming multidrug resistance in cancer [30].

5.2 Controlled and Stimuli-Responsive Release

Hybrid nanocarriers allow fine-tuning of release profiles, from sustained and controlled release to triggered, stimuli-responsive release. Controlled release is often achieved by polymer degradation, diffusion through lipid layers, or desorption from inorganic surfaces. For example, biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) degrade hydrolytically, gradually releasing encapsulated drugs [31].

Stimuli-responsive mechanisms introduce an additional layer of sophistication. pH-sensitive hybrids release drugs preferentially in acidic tumor microenvironments, while redox-responsive systems exploit elevated intracellular glutathione concentrations to trigger drug release. Thermoresponsive polymers combined with gold nanoparticles enable on-demand release upon laser irradiation, merging chemotherapy with photothermal therapy. Similarly, magnetically responsive hybrids release drugs under alternating magnetic fields, permitting deep-tissue targeting [32].

5.3 Multi-Drug Co-Delivery

One of the most transformative capabilities of hybrid nanocarriers is the simultaneous delivery of multiple drugs or drug–gene combinations. This strategy enhances therapeutic efficacy by attacking disease pathways from different angles while reducing resistance development. For example, polymer–lipid–gold hybrids have been used to co-deliver doxorubicin and siRNA targeting P-glycoprotein, leading to synergistic tumor regression and reversal of multidrug resistance [33].

5.4 Kinetic Modeling of Drug Release

Mathematical modeling is often applied to describe release kinetics from hybrid systems. Common models include Higuchi (diffusion-based), Korsmeyer–Peppas (anomalous transport), and zero-order (constant release). Hybrids frequently demonstrate biphasic release with an initial burst followed by sustained release, which can be minimized by optimizing lipid shell thickness or polymer cross-linking. Such predictive models guide formulation design and clinical dosing schedules [34].

6.0 Therapeutic Applications of Hybrid Nanocarriers

Hybrid nanocarriers have been extensively studied for a wide spectrum of therapeutic areas owing to their versatility and multifunctionality. The integration of polymers, lipids, and inorganic materials has made them particularly valuable in oncology, infectious diseases, neurological disorders, cardiovascular diseases, and regenerative medicine [35,36].

6.1 Oncology

Cancer remains the foremost application of hybrid nanocarriers due to the urgent need for effective, targeted therapies with minimal systemic toxicity. Hybrid systems enable tumor-targeted delivery via EPR effect, ligand-mediated targeting, and stimuli-responsive release. In polymer–lipid–gold hybrids, photothermal therapy is combined with chemotherapy to achieve synergistic cytotoxicity. Mesoporous silica–lipid–polymer hybrids allow co-delivery of cisplatin and siRNA to silence oncogenes, thereby overcoming resistance [37]. Furthermore, imaging functionalities such as MRI and fluorescence can be integrated for real-time theranostics.

6.2 Infectious Diseases

Hybrid nanocarriers improve antimicrobial efficacy by enhancing intracellular delivery, preventing drug efflux, and disrupting biofilms. For instance, lipid–polymer hybrids loaded with rifampicin demonstrate enhanced macrophage uptake and improved clearance of *Mycobacterium tuberculosis* [38]. Silver- or zinc oxide-based inorganic hybrids coated with lipids have shown synergistic antibacterial and antifungal activity, suitable for wound healing applications.

6.3 Neurological Disorders

Crossing the blood–brain barrier (BBB) remains a formidable challenge in neuropharmacology. Hybrid nanocarriers, especially polymer–lipid–magnetic nanoparticle systems, enhance BBB penetration via magnetic guidance and receptor-mediated transcytosis. Curcumin-loaded lipid–polymer hybrids coated with gold nanoparticles have shown promising results in Alzheimer's disease models, enabling both therapeutic delivery and imaging [39].

6.4 Cardiovascular and Metabolic Diseases

Hybrid nanocarriers also hold potential in cardiovascular therapy by delivering anti-thrombotic agents, statins, or nucleic acids. For instance, polymer–lipid–iron oxide hybrids have been explored for targeted delivery of siRNA against PCSK9, thereby lowering cholesterol levels [40]. Similarly, in diabetes, hybrid nanoparticles have been used to deliver insulin in a controlled and prolonged manner.

6.5 Regenerative Medicine and Gene Therapy

In tissue engineering, hybrid nanocarriers facilitate the delivery of growth factors, genes, and stem cell modulators. Lipid–polymer hybrids coated with bioactive inorganic components such as hydroxyapatite support osteogenesis and bone regeneration. In gene therapy, hybrid systems protect nucleic acids from degradation while ensuring efficient cellular uptake and endosomal escape [41].

7.0 Overcoming Biological Barriers with Hybrid Nanocarriers

A major challenge in nanomedicine is the multitude of biological barriers that limit drug delivery efficacy. These include systemic clearance by the reticuloendothelial system (RES), enzymatic degradation in circulation, the endothelial barrier for tissue penetration, the extracellular matrix in tumors, and the blood–brain barrier (BBB) in neurological disorders. Hybrid nanocarriers, by virtue of their synergistic architecture, are uniquely suited to navigate these barriers more effectively than single-component systems [42,43].

7.1 Avoidance of Reticuloendothelial System Clearance

Nanocarriers are often opsonized by plasma proteins, leading to rapid clearance by macrophages in the liver and spleen. Incorporation of a lipid shell, particularly with polyethylene glycol (PEG) modification, creates a “stealth” effect by reducing protein adsorption and prolonging circulation. Polymer layers further enhance stability and prevent premature disintegration. Inorganic materials, such as gold or silica, coated with polymers and lipids, maintain stealth properties while offering imaging contrast [44].

7.2 Enhanced Tissue Penetration and Tumor Accumulation

Hybrid nanocarriers exploit the enhanced permeability and retention (EPR) effect for passive tumor targeting, while surface ligands such as folate, transferrin, or antibodies enable active targeting. Moreover, the rigidity provided by inorganic components can help hybrids maintain shape during interstitial transport, while lipid flexibility facilitates membrane fusion for cellular entry. Matrix-degrading enzyme coatings, such as hyaluronidase, further enhance penetration through tumor stroma [45].

7.3 Blood–Brain Barrier Crossing

Crossing the BBB remains one of the most formidable obstacles in neuropharmacology. Hybrid nanocarriers provide multiple strategies, including surface modification with transferrin, lactoferrin, or apolipoproteins to exploit receptor-mediated transport. Magnetic nanoparticles incorporated into lipid–polymer hybrids can be directed across the BBB using external magnetic fields. Stimuli-responsive polymers facilitate release of drugs once inside the CNS microenvironment [46].

7.4 Intracellular Trafficking and Endosomal Escape

Once internalized by endocytosis, nanocarriers often face entrapment in endolysosomal compartments. Hybrid systems overcome this by employing cationic polymers such as polyethyleneimine that exert the “proton sponge effect,” rupturing endosomes. Lipid bilayers aid in membrane fusion and cytosolic delivery, while photothermal inorganic nanoparticles induce localized heating to disrupt endosomal membranes [47]. These multi-pronged approaches significantly enhance intracellular delivery of nucleic acids and proteins. By integrating strategies to overcome systemic, tissue, and intracellular barriers, hybrid nanocarriers enhance therapeutic efficacy while minimizing off-target toxicity, thus standing out as superior platforms in drug delivery.

8.0 Theranostic Applications of Hybrid Nanocarriers

Theranostics, the integration of therapy and diagnostics into a single platform, has emerged as a frontier in precision medicine. Hybrid nanocarriers are ideally suited for theranostics because they combine therapeutic payloads with inorganic components that provide imaging or stimulus-responsiveness [48].

8.1 Imaging Capabilities

Inorganic nanoparticles such as iron oxide, gold, and quantum dots impart unique imaging modalities. Iron oxide confers magnetic resonance imaging (MRI) contrast, while gold nanoparticles enhance computed tomography (CT) signals and enable photoacoustic imaging. When combined with polymers and lipids, these imaging functions are coupled with controlled drug release, allowing simultaneous visualization and treatment [49].

8.2 Photothermal and Photodynamic Therapy

Gold nanorods, nanoshells, and carbon-based nanomaterials incorporated into hybrids enable photothermal therapy (PTT) upon near-infrared irradiation, converting light energy into localized heat that ablates tumors. Lipid and polymer components stabilize the gold core and co-deliver chemotherapeutics, creating synergistic effects. Similarly, hybrid systems loaded with photosensitizers and inorganic nanomaterials enable photodynamic therapy (PDT), where light-induced reactive oxygen species (ROS) kill cancer cells [50].

8.3 Combination of Diagnosis and Therapy

The most transformative aspect of hybrid theranostics is real-time feedback on therapeutic efficacy. For example, mesoporous silica–lipid–polymer hybrids can encapsulate doxorubicin and simultaneously track drug release via fluorescent inorganic cores. Iron oxide–based hybrids allow MRI monitoring of tumor accumulation while delivering siRNA or chemotherapeutics. Such systems enable “see-and-treat” paradigms, revolutionizing personalized medicine [51].

8.4 Emerging Theranostic Applications Beyond Oncology

While cancer dominates theranostic applications, hybrids are being explored in cardiovascular and neurological diseases. Iron oxide hybrids have been tested for tracking stem cell therapy in cardiac repair, while polymer–lipid–gold systems enable targeted delivery of neuroprotective agents with concurrent brain imaging. In infectious diseases, silver- or zinc-based hybrids offer both antimicrobial activity and diagnostic tracking of infection sites [52]. Thus, hybrid nanocarriers embody multifunctional theranostic systems that unite diagnosis, monitoring, and therapy in a single construct, fulfilling the promise of precision nanomedicine.

9.0 Clinical Translation Challenges of Hybrid Nanocarriers

Despite promising preclinical outcomes, hybrid nanocarriers face significant challenges in translation to clinical practice. These challenges arise from issues of large-scale manufacturing, reproducibility, safety, pharmacokinetics, regulatory approval, and cost-effectiveness [53,54].

9.1 Manufacturing and Scalability

The fabrication of hybrid systems often involves multiple steps, such as polymer synthesis, lipid coating, and inorganic nanoparticle incorporation, which may hinder large-scale reproducibility. Batch-to-batch variability in size, drug loading, and release profiles complicates regulatory compliance. Microfluidic technologies and continuous manufacturing platforms are being investigated to ensure scalability and reproducibility [55].

9.2 Safety and Toxicity Concerns

While lipids and biodegradable polymers are generally safe, the inclusion of inorganic materials raises toxicity concerns. Gold nanoparticles, silica, and quantum dots may accumulate in organs, causing long-term toxicity. Careful surface functionalization, biodegradable inorganic alternatives, and thorough toxicological

evaluation are required to mitigate risks. Regulatory authorities demand extensive biocompatibility testing before clinical use [56].

9.3 Pharmacokinetics and Biodistribution

Complex architectures make predicting pharmacokinetics challenging. Inorganic materials may alter clearance pathways compared to purely polymeric or lipidic systems. Biodistribution studies indicate preferential accumulation in the liver and spleen, raising concerns about chronic toxicity. Designing hybrids with optimized size, charge, and surface properties is essential to achieve predictable pharmacokinetic profiles [57].

9.4 Regulatory Hurdles

Current regulatory frameworks are primarily designed for conventional drugs or simple nanocarriers. The multifunctionality of hybrid systems blurs the boundaries between drugs, devices, and combination products, complicating classification. Harmonization of guidelines by agencies such as FDA, EMA, and PMDA is required to streamline approval pathways. Regulatory emphasis is placed on stability, reproducibility, and validated manufacturing methods [58].

9.5 Economic and Cost-Effectiveness Issues

Hybrid nanocarriers, due to their complex fabrication and use of inorganic materials, often entail high production costs. Cost-effectiveness compared to existing therapies remains a critical consideration for adoption in healthcare systems. Strategies such as scaling-up microfluidics and simplifying hybrid designs may reduce costs. Partnerships between academia, industry, and regulatory bodies will be essential to accelerate commercialization [59]. In summary, while hybrid nanocarriers hold immense therapeutic promise, overcoming translational barriers requires advances in scalable manufacturing, comprehensive safety evaluations, regulatory harmonization, and economic optimization.

Table 2. Advantages and Limitations of Hybrid Nanocarriers Compared to Single-Component Systems

Parameter	Polymeric Systems	Lipid Systems	Inorganic Systems	Hybrid Systems (Polymer–Lipid–Inorganic)
Mechanical stability	High	Moderate	Very high	Optimized balance
Biocompatibility	Good	Excellent	Variable	Excellent (due to lipid coating)
Drug loading versatility	Moderate	Limited	High (mesoporous cores)	Very high
Controlled/stimuli release	Excellent	Limited	Excellent	Tunable multi-stimuli
Imaging/diagnostic ability	Limited	Limited	Excellent	Integrated multimodal
Scalability	Good	Good	Complex	Moderate (microfluidics required)
Regulatory familiarity	Established	Established	Developing	Emerging
Safety profile	Good	Excellent	Dose-dependent toxicity	Improved with coatings



Figure 1. Structural Architecture and Functional Integration in Hybrid Nanocarriers

10.0 Future Perspectives of Hybrid Nanocarriers

The field of hybrid nanocarriers stands at the intersection of material science, pharmaceutical technology, and clinical medicine, offering unprecedented opportunities to redefine the future of drug delivery. While significant progress has been made, the full potential of polymer–lipid–inorganic hybrids is yet to be realized. Several emerging directions warrant attention to accelerate translation from bench to bedside [60,61]. One of the most promising areas lies in the integration of artificial intelligence (AI) and machine learning (ML) to predict formulation behavior, optimize component ratios, and simulate pharmacokinetics in silico. Such computational tools can significantly reduce experimental burden, streamline preclinical development, and improve reproducibility. AI-guided nanocarrier design may also enable patient-specific customization by accounting for genetic, metabolic, and disease-specific variables [62]. The concept of personalized nanomedicine is expected to expand, where hybrid nanocarriers are tailored to individual patients based on tumor genotyping, proteomic profiling, or biomarker expression. For example, designing hybrid carriers that selectively respond to a patient's tumor microenvironmental pH or enzymatic signature may maximize therapeutic efficacy while minimizing systemic toxicity [63]. This approach aligns with the broader shift toward precision medicine in oncology, neurology, and infectious diseases. Another frontier is the development of biodegradable inorganic components. Although traditional inorganic nanoparticles such as gold or silica exhibit excellent functionality, their persistence in tissues raises toxicity concerns. Research is moving toward bioresorbable alternatives, including calcium phosphate, magnesium-based nanoparticles, or iron oxide derivatives that degrade into physiologically acceptable ions [64]. These innovations could mitigate long-term safety risks and facilitate regulatory approval.

Combination therapies will also play a pivotal role. Hybrid nanocarriers enable co-delivery of chemotherapeutics, nucleic acids, and immunomodulators, providing a single platform for multimodal therapy. The ability to integrate photothermal or photodynamic agents with conventional drugs could revolutionize cancer therapy by combining tumor ablation, immune activation, and targeted chemotherapy in one step [65]. Additionally, hybrid nanocarriers are poised to transform regenerative medicine by delivering growth factors, exosomes, or CRISPR-Cas9 gene editing systems. Inorganic scaffolds such as hydroxyapatite can be integrated into polymer–lipid hybrids for bone regeneration, while magnetic nanoparticles may guide stem cell differentiation under controlled magnetic fields [66]. Such multifunctional platforms bridge the gap between nanomedicine and tissue engineering. Finally, integration with smart biomedical devices represents a futuristic vision. Hybrid nanocarriers embedded in microneedle patches, implantable pumps, or wearable biosensors could provide controlled release in response to real-time physiological feedback. Coupling with digital health technologies may allow remote monitoring, adaptive dosing, and enhanced patient compliance [67]. Overall, the

future of hybrid nanocarriers lies in multidisciplinary innovation, regulatory adaptation, and patient-centered customization. With continued advances, these platforms are poised to become cornerstone technologies in precision therapeutics and theranostics.

11.0 Conclusion

Hybrid nanocarriers that integrate polymers, lipids, and inorganic materials represent a transformative advancement in the field of drug delivery. By leveraging the complementary strengths of each material class, these systems overcome the limitations of single-component carriers and enable multifunctionality, including high drug loading, controlled and stimuli-responsive release, enhanced barrier penetration, and theranostic capabilities. Their applications span oncology, infectious diseases, neurology, cardiovascular disorders, and regenerative medicine, underscoring their versatility. Despite significant promise, translation to the clinic is constrained by challenges in scalability, reproducibility, toxicity assessment, pharmacokinetics, and regulatory approval. Addressing these barriers will require concerted efforts involving novel fabrication technologies, AI-driven optimization, development of biodegradable inorganic materials, and harmonized regulatory frameworks. Future directions highlight patient-specific customization, multimodal therapies, and integration with digital health platforms, signaling a paradigm shift toward personalized nanomedicine. In conclusion, hybrid nanocarriers stand as a beacon of innovation in nanomedicine. They not only enhance therapeutic efficacy but also bring diagnostics and therapy into a unified platform, paving the way for truly precision-driven and patient-centric healthcare in the 21st century.

References

1. Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24(3):179–191.
2. Wang H, Zhao Y, Wu Y, Hu YL, Nan K, Nie G, Chen H. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG–PLGA copolymer nanoparticles. Biomaterials. 2011;32(32):8281–8290.
3. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–827.
4. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003.
5. Li J, Kataoka K. Functionalized polymeric micelles for biomedical applications. Adv Mater. 2020;32(13):1803322.
6. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34–47.
7. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 2013;65(13–14):1803–1815.
8. Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: State of the art, emerging technologies, and perspectives. Int J Nanomedicine. 2019;14:1937–1952.
9. Souri M, Soltani F, Fathi M, Hashemi M. Hybrid nanoparticles in drug delivery: Recent progress and future perspectives. J Drug Deliv Sci Technol. 2021;61:102145.
10. Zhang R, Xue M, Li F, Chen C, Luo L, Xu Z. Lipid–polymer hybrid nanoparticles: Synthesis, characterization and applications in drug delivery. J Mater Chem B. 2020;8(17):3509–3521.
11. Chen F, Hong H, Zhang Y, Valdovinos HF, Shi S, Kwon GS, Theuer CP, Barnhart TE, Cai W. In vivo tumor targeting and imaging with polymer–inorganic hybrid nanoparticles. ACS Nano. 2013;7(10):9027–9039.
12. Song J, Huang P, Duan H, Chen X. Lipid–inorganic hybrid nanoparticles for biomedical imaging and cancer therapy. Nano Today. 2016;11(2):167–187.
13. Luo D, Carter KA, Miranda D, Lovell JF. Chemophototherapy: An emerging treatment option for solid tumors. Adv Sci. 2017;4(1):1600106.
14. Nguyen DN, Green JJ, Chan JM, Langer R, Anderson DG. Polymeric materials for gene delivery and DNA vaccination. Adv Mater. 2009;21(8):847–867.
15. Hood RR, DeVoe DL. High-throughput continuous flow production of nanosized liposomes by microfluidic vertical flow focusing. Small. 2015;11(43):5790–5799.
16. Fülöp T, Kappel K, Kovács A, et al. Nanoprecipitation-based fabrication of nanoparticles for drug

delivery: Current status and future outlook. Adv Drug Deliv Rev. 2022;186:114356.
17. Li W, Szoka FC. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res. 2007;24(3):438–449.
18. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
19. De Koker S, Hoogenboom R, De Geest BG. Polymeric multilayer capsules for drug delivery. Chem Soc Rev. 2012;41(7):2867–2884.
20. Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol. 2012;7(10):623–629.
21. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
22. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–951.
23. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int Immunopharmacol. 2003;3(3):319–328.
24. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–198.
25. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278–1288.
26. Chen Q, Liang C, Wang C, Liu Z. An imagable and photothermal "abraxane-like" nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors. Adv Mater. 2015;27(5):903–910.
27. Mohapatra A, Harilal S, Sahoo CK, et al. A review on controlled drug delivery systems. J Adv Pharm Technol Res. 2020;11(1):10–18.
28. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release. 2012;161(2):505–522.
29. Rosenholm JM, Sahlgren C, Lindén M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles–opportunities & challenges. Nanoscale. 2010;2(10):1870–1883.
30. Xu CF, Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci. 2015;10(1):1–12.
31. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377–1397.
32. Meng F, Zhong Z, Feijen J. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules. 2009;10(2):197–209.
33. Meng H, Wang M, Liu H, Liu X, Situ A, Wu B, Ji Z, Chang CH, Nel AE. Use of a lipid–coated mesoporous silica nanoparticle platform for synergistic gemcitabine and siRNA delivery to human pancreatic cancer. Biomaterials. 2015;34(13):3479–3491.
34. Siepmann J, Siepmann F. Modeling of diffusion controlled drug delivery. J Control Release. 2012;161(2):351–362.
35. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8(6):2101–2141.
36. Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: Focus on cancer. Int J Nanomedicine. 2014;9:467–483.
37. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: Interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine. 2007;2(5):681–693.
38. Pandey R, Khuller GK. Nanoparticle-based oral drug delivery system for an injectable antibiotic streptomycin. Tuberculosis. 2007;87(6):531–536.
39. Kurapati R, Grover P. Hybrid nanoparticles for brain delivery: Crossing the blood–brain barrier. Drug Discov Today. 2021;26(4):871–882.
40. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51.
41. Bose S, Tarafder S. Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: A review. Acta Biomater. 2012;8(4):1401–1421.
42. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–627.
43. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–515.
44. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93–102.
45. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–664.
46. Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B.

2016;6(4):268–286.
47. Sonawane ND, Szoka FC Jr, Verkman AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine–DNA polyplexes. J Biol Chem. 2003;278(45):44826–44831.
48. Kelkar SS, Reineke TM. Theranostics: Combining imaging and therapy. Bioconjug Chem. 2011;22(10):1879–1903.
49. Li L, Tong R, Li M, Kohane DS. Self-assembled nanomaterials for theranostic applications. Acc Chem Res. 2021;54(6):1346–1359.
50. Chatterjee DK, Yong Z. Upconverting nanoparticles as nanotransducers for photodynamic therapy in cancer treatment. Nanomedicine. 2008;3(1):73–82.
51. Zhen Z, Tang W, Chuang YJ, Todd T, Zhang W, Lin X, Niu G, Liu G, Wang L, Pan Z, Chen X, Xie J. Tumor vasculature targeted photodynamic therapy for enhanced delivery of nanoparticles. ACS Nano. 2014;8(6):6004–6013.
52. Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol. 2015;88(1054):20150207.
53. van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJ, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14(11):1007–1017.
54. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev. 2017;108:25–38.
55. Hood RR, Vreeland WN, DeVoe DL. Microfluidic remote loading for rapid single-step liposomal drug preparation. Lab Chip. 2014;14(17):3359–3367.
56. Kingston BR, Syed AM, Ngai J, Sindhwani S, Chan WC. Assessing micromaterial safety in nanomedicine. Nat Nanotechnol. 2020;15(8):590–602.
57. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WC. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.
58. Tinkle S, McNeil SE, Mühlebach S, Bawa R, Borchard G, Barenholz Y, Tamarkin L, Desai N. Nanomedicines: Addressing the scientific and regulatory gap. Ann N Y Acad Sci. 2014;1313:35–56.
59. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.
60. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10–29.
61. Bregoli L, Chiarini F, Gambarelli A, Sighinolfi G, Gatti AM, Santi P, Cinti C. Toxicity of engineered nanoparticles in cancer therapy. Cancer Nanotechnol. 2012;3(1–6):2.
62. Li Y, Lee J, He C, Zhang J, Xu Z, Chen H, Zou Y, Chen S, Jin Y, Liu Y. Machine learning-guided design of nanomedicines. Adv Drug Deliv Rev. 2022;185:114297.
63. Gong H, Chao Y, Xiang J, Han X, Song G, Feng L, Liu J, Yang G, Chen Q, Liu Z. Hyaluronidase to enhance nanoparticle-based photodynamic tumor therapy. Nano Lett. 2016;16(4):2512–2521.
64. Zhang Y, Xu C, Yang X, Li Y, Fang L, Zhu L, Sun H. Biodegradable inorganic nanoparticles for biomedical applications. Adv Mater. 2021;33(33):2007390.
65. Yang G, Phua SZ, Bindra AK, Zhao Y. Degradability and clearance of inorganic nanoparticles for biomedical applications. Adv Mater. 2019;31(10):1805730.
66. Bose S, Roy M, Bandyopadhyay A. Recent advances in bone tissue engineering scaffolds. Trends Biotechnol. 2012;30(10):546–554.
67. Yetisen AK, Martinez-Hurtado JL, Ünal B, Khademhosseini A, Butt H. Wearables in medicine. Adv Mater. 2018;30(33):1706910.